MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
Boundless Bio, Inc. (NASDAQ: BOLD)*
Organization & Developments: Boundless Bio
Parents
Boundless Bio, Inc. (NASDAQ: BOLD)*
Children
* ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
*Treating oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification
2024: Boundless Bio bumps IPO market back to life after sleepy few weeks
2024: Boundless Bio Starts $100 Million U.S. IPO Plan_ seekingalpha.com
Jumps
Finance & Acquisitions: Boundless Bio
Key People: Boundless Bio